Jaguar Health Q3 GAAP EPS $(0.38) Beats $(1.23) Estimate, Sales $2.81M Beat $2.46M Estimate
Portfolio Pulse from Benzinga Newsdesk
Jaguar Health (NASDAQ:JAGX) reported Q3 GAAP EPS of $(0.38), surpassing the $(1.23) estimate, and sales of $2.81M, exceeding the $2.46M estimate. This reflects a significant reduction in losses and a slight decrease in sales compared to the same period last year.
November 14, 2023 | 1:03 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Jaguar Health reported better-than-expected Q3 earnings and sales, indicating a substantial reduction in losses compared to last year.
Beating both EPS and sales estimates typically generates positive investor sentiment, which can lead to a short-term increase in stock price. The significant improvement in losses year-over-year is particularly encouraging for investors.
CONFIDENCE 85
IMPORTANCE 90
RELEVANCE 100